Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Shares Bought by Point72 Asset Management L.P.

Point72 Asset Management L.P. boosted its stake in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 102.5% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 750,235 shares of the company's stock after purchasing an additional 379,828 shares during the period. Point72 Asset Management L.P. owned approximately 2.27% of Lexeo Therapeutics worth $4,937,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp grew its position in shares of Lexeo Therapeutics by 5.6% during the 4th quarter. Bank of New York Mellon Corp now owns 50,660 shares of the company's stock valued at $333,000 after acquiring an additional 2,677 shares during the period. JPMorgan Chase & Co. grew its position in shares of Lexeo Therapeutics by 30.1% during the 4th quarter. JPMorgan Chase & Co. now owns 13,371 shares of the company's stock valued at $88,000 after acquiring an additional 3,093 shares during the period. Wells Fargo & Company MN grew its position in shares of Lexeo Therapeutics by 49.9% during the 4th quarter. Wells Fargo & Company MN now owns 11,156 shares of the company's stock valued at $73,000 after acquiring an additional 3,714 shares during the period. Rhumbline Advisers grew its position in shares of Lexeo Therapeutics by 19.6% during the 4th quarter. Rhumbline Advisers now owns 25,197 shares of the company's stock valued at $166,000 after acquiring an additional 4,127 shares during the period. Finally, Barclays PLC grew its position in shares of Lexeo Therapeutics by 9.9% during the 4th quarter. Barclays PLC now owns 55,161 shares of the company's stock valued at $363,000 after acquiring an additional 4,951 shares during the period. 60.67% of the stock is owned by institutional investors and hedge funds.

Lexeo Therapeutics Price Performance

LXEO traded down $0.26 during trading on Friday, reaching $2.82. The company's stock had a trading volume of 480,722 shares, compared to its average volume of 490,973. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01. The firm has a fifty day simple moving average of $3.09 and a two-hundred day simple moving average of $4.75. Lexeo Therapeutics, Inc. has a 1 year low of $1.45 and a 1 year high of $19.50. The company has a market cap of $93.62 million, a price-to-earnings ratio of -0.89 and a beta of 1.27.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.99) earnings per share for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.19). As a group, analysts anticipate that Lexeo Therapeutics, Inc. will post -3.14 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. HC Wainwright dropped their target price on Lexeo Therapeutics from $23.00 to $15.00 and set a "buy" rating on the stock in a research report on Friday, May 16th. Chardan Capital lowered their price objective on Lexeo Therapeutics from $22.00 to $20.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. Leerink Partners lowered their price objective on Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating on the stock in a report on Monday, March 24th. Finally, Royal Bank of Canada lowered their price objective on Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating on the stock in a report on Tuesday, March 25th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Lexeo Therapeutics has an average rating of "Buy" and an average target price of $20.20.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.